Unicycive Resubmits Key Kidney Drug NDA, Eyes June 2026 FDA Decision

TL;DR

**UNCY's future hinges on a single FDA decision for OLC by June 2026; it's a high-stakes bet on regulatory approval and market acceptance.**

AI Summary

Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company focused on kidney disease, with two primary drug candidates: oxylanthanum carbonate (OLC) for hyperphosphatemia in CKD patients on dialysis, and UNI-494 for acute kidney injury (AKI). The company reported no product revenue to date. OLC, a next-generation phosphate binder, leverages nanoparticle technology to reduce pill burden and improve palatability. Its New Drug Application (NDA) was resubmitted to the FDA in December 2025 after a Complete Response Letter (CRL) in June 2025, which cited deficiencies at a third-party manufacturing vendor. The FDA accepted the resubmission in January 2026, setting a PDUFA target action date of June 29, 2026. UNI-494 completed a Phase I clinical study in healthy volunteers in 2024, targeting AKI, a condition with no FDA-approved medicines and affecting over 2 million U.S. patients annually, costing the healthcare system over $9 billion per year. The company's strategy involves in-licensing technologies and drugs, with an initial focus on U.S. regulatory approval before seeking global partnerships.

Why It Matters

Unicycive's progress with oxylanthanum carbonate (OLC) is critical for investors, as FDA approval could mark the company's first product revenue, significantly impacting its financial viability. For the estimated 450,000 U.S. dialysis patients struggling with hyperphosphatemia, OLC offers a potential improvement over existing phosphate binders by reducing pill burden and improving palatability, addressing a major adherence issue. In the competitive renal disease market, a successful launch of OLC could position Unicycive as an innovator, while UNI-494's potential as a first-in-class AKI treatment could disrupt a market with no approved therapies, offering hope for over 2 million affected U.S. patients and potentially reducing the $9 billion annual healthcare cost.

Risk Assessment

Risk Level: high — The company has generated no product revenue to date and explicitly states its future profitability is uncertain, indicating a high reliance on its pipeline. The June 2025 Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) due to a third-party manufacturing vendor's cGMP deficiencies highlights significant regulatory and supply chain risks, despite the resubmission and new PDUFA date of June 29, 2026.

Analyst Insight

Investors should closely monitor the FDA's decision on oxylanthanum carbonate (OLC) by the June 29, 2026 PDUFA date, as this is the primary near-term catalyst for Unicycive's valuation. Given the high-risk profile and lack of current revenue, consider this a speculative investment with potential for significant volatility based on regulatory outcomes.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

+0%

Key Numbers

• $64.3M — Market Value (Aggregate market value of non-affiliate voting stock as of June 30, 2025, indicating current market capitalization.)
• 25.2M — Shares Outstanding (Number of common stock shares outstanding as of March 30, 2026, relevant for per-share calculations.)
• June 29, 2026 — PDUFA Target Date (Critical FDA target action date for oxylanthanum carbonate NDA, directly impacting potential market entry.)
• 0 — Product Revenue (Product revenue generated to date, highlighting the company's pre-commercial stage and reliance on pipeline success.)
• 36M — Americans with CKD (Number of Americans affected by Chronic Kidney Disease, representing the target market size for OLC.)
• 550K — ESRD Patients (Number of Americans with end-stage renal disease requiring dialysis, a subset of the target market for OLC.)
• 450K — Dialysis Patients on Phosphate Binders (Estimated number of U.S. dialysis patients taking phosphate binders, indicating the immediate addressable market for OLC.)
• 2M — AKI Patients (Number of U.S. patients affected by Acute Kidney Injury annually, representing the target market for UNI-494.)
• $9B — AKI Healthcare Cost (Annual cost to the U.S. healthcare system due to AKI, highlighting the economic burden UNI-494 aims to address.)
• 75% — Uncontrolled Hyperphosphatemia (Percentage of U.S. dialysis patients with uncontrolled hyperphosphatemia, underscoring the unmet medical need OLC targets.)

Key Players & Entities

• Unicycive Therapeutics, Inc. (company) — clinical-stage biotechnology company
• oxylanthanum carbonate (company) — investigational next-generation phosphate binding agent
• UNI-494 (company) — novel drug candidate for acute kidney injury
• FDA (regulator) — U.S. Food and Drug Administration
• Spectrum Pharmaceuticals (company) — original developer of oxylanthanum carbonate
• Sphaera Pharma (company) — original developer of UNI-494
• $64,310,247 (dollar_amount) — aggregate market value of voting stock held by non-affiliates as of June 30, 2025
• $4.77 (dollar_amount) — closing price of common stock on Nasdaq Capital Market as of June 30, 2025
• The Nasdaq Stock Market, LLC (regulator) — exchange where UNCY common stock is registered
• SEC (regulator) — U.S. Securities and Exchange Commission

FAQ

Risk Factors

• FDA Approval Dependency [high — regulatory]: The company's success is heavily reliant on obtaining FDA approval for its drug candidates, particularly oxylanthanum carbonate (OLC). A Complete Response Letter (CRL) was issued in June 2025 for OLC due to manufacturing vendor deficiencies, highlighting the critical nature of manufacturing quality and regulatory compliance. The PDUFA target action date for the resubmitted NDA is June 29, 2026.
• Pre-Commercial Stage and Burn Rate [high — financial]: Unicycive Therapeutics is a clinical-stage company with no product revenue to date. The company's operations are funded through equity financings and potentially debt. Significant ongoing investment is required for clinical trials, manufacturing, and regulatory submissions, leading to a substantial cash burn rate.
• Competition in Phosphate Binders [medium — market]: The market for hyperphosphatemia treatments, specifically phosphate binders for CKD patients on dialysis, is competitive. While OLC aims to address limitations of existing binders (potency, pill burden, palatability), it faces established competitors. The estimated 450,000 dialysis patients on phosphate binders represent the immediate addressable market, with 75% experiencing uncontrolled hyperphosphatemia.
• Unmet Need in Acute Kidney Injury (AKI) [medium — market]: UNI-494 targets AKI, a condition affecting over 2 million U.S. patients annually with no FDA-approved medicines. While this represents a significant unmet need and a large potential market, the development and approval pathway for novel AKI treatments can be complex and lengthy.
• Third-Party Manufacturing Reliance [high — operational]: The CRL for OLC was attributed to deficiencies at a third-party manufacturing vendor. This highlights the operational risk associated with relying on external partners for critical manufacturing processes. Ensuring quality control and compliance across all vendors is paramount for regulatory success.
• Future Financing Needs [high — financial]: As a clinical-stage company, Unicycive will likely require significant future capital to fund ongoing clinical trials, potential commercialization activities, and general operations. The ability to secure this financing through equity offerings, debt, or partnerships will be critical for its continued existence.

Industry Context

Unicycive Therapeutics operates in the highly competitive biotechnology sector, focusing on the niche but significant area of kidney disease therapies. The company's strategy of in-licensing assets is common in the industry, aiming to leverage existing technologies and reduce early-stage R&D risk. Key trends include the increasing prevalence of chronic diseases like CKD and the persistent unmet need in areas like AKI, driving demand for innovative treatments.

Regulatory Implications

The company's primary regulatory hurdle is the FDA approval process for its drug candidates. The recent CRL for oxylanthanum carbonate underscores the critical importance of manufacturing quality and vendor compliance. Successful navigation of these regulatory pathways is essential for market entry and commercial viability.

What Investors Should Do

1. Monitor the PDUFA target action date for OLC (June 29, 2026).
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape for both OLC and UNI-494.
4. Track progress on UNI-494 clinical development.

Key Dates

• 2025-06-01: Complete Response Letter (CRL) for OLC NDA — Indicated deficiencies at a third-party manufacturing vendor, requiring resubmission and delaying potential market entry.
• 2025-12-01: Resubmission of OLC NDA — Addressed the deficiencies cited in the CRL, moving the OLC application back into the FDA review process.
• 2026-01-01: FDA Acceptance of OLC NDA Resubmission — Confirmed the resubmitted application met filing requirements, initiating a new review cycle.
• 2026-06-29: PDUFA Target Action Date for OLC — The critical date by which the FDA is expected to make a decision on the OLC New Drug Application, directly impacting commercialization prospects.
• 2024-01-01: Completion of UNI-494 Phase I Clinical Study — Successfully completed initial safety and tolerability study in healthy volunteers, paving the way for further development in AKI patients.

Glossary

Hyperphosphatemia

A condition characterized by abnormally high levels of phosphate in the blood. (This is the primary indication for Unicycive's drug candidate oxylanthanum carbonate (OLC), which aims to treat this condition in CKD patients on dialysis.)

Chronic Kidney Disease (CKD)

A progressive condition characterized by the gradual loss of kidney function over time. (This is the broad patient population for OLC. Approximately 36 million Americans have CKD, with a significant subset requiring dialysis.)

End-Stage Renal Disease (ESRD)

The final stage of chronic kidney disease, where the kidneys have failed and require dialysis or a kidney transplant to sustain life. (A key sub-population for OLC, as approximately 550,000 Americans have ESRD and require dialysis, many of whom suffer from hyperphosphatemia.)

Phosphate Binder

A medication taken with meals that binds to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. (OLC is a next-generation phosphate binder designed to improve upon existing treatments for hyperphosphatemia in dialysis patients.)

Acute Kidney Injury (AKI)

A sudden and rapid loss of kidney function that occurs as a result of illness, injury, or a blockage in the urinary tract. (This is the target indication for Unicycive's drug candidate UNI-494, a condition with significant unmet medical need and no FDA-approved treatments.)

PDUFA Target Action Date

The date by which the U.S. Food and Drug Administration (FDA) is expected to make a decision on a New Drug Application (NDA) or Biologics License Application (BLA). (This date (June 29, 2026, for OLC) is critical for investors as it signifies the potential approval and market entry timeline for the drug.)

Complete Response Letter (CRL)

A letter issued by the FDA to an applicant when it has determined that an application cannot be approved in its present form. (Unicycive received a CRL for OLC in June 2025, indicating manufacturing deficiencies that needed to be addressed before resubmission.)

Year-Over-Year Comparison

As a clinical-stage company with no product revenue, year-over-year comparisons of revenue and margins are not applicable. The primary focus for comparison would be on the progression of clinical trials and regulatory milestones. The key development since the last filing is the resubmission of the NDA for oxylanthanum carbonate following a Complete Response Letter, with a new PDUFA target action date set for June 29, 2026. This indicates progress in addressing manufacturing deficiencies, but also highlights the inherent risks in the regulatory approval process.

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share UNCY The Nasdaq Stock Market,
• $4.77 — ice of the registrant's common stock of $4.77 on The Nasdaq Capital Market as of that
• $9 billion — osts the healthcare system in excess of $9 billion per year. More than 300,000 patients pe

Filing Documents

• ea0281982-10k_unicycive.htm (10-K) — 1684KB
• ea028198201ex4-4.htm (EX-4.4) — 7KB
• ea028198201ex23-1.htm (EX-23.1) — 2KB
• ea028198201ex31-1.htm (EX-31.1) — 10KB
• ea028198201ex31-2.htm (EX-31.2) — 10KB
• ea028198201ex32-1.htm (EX-32.1) — 4KB
• ea028198201ex32-2.htm (EX-32.2) — 4KB
• ea028198201_img1.jpg (GRAPHIC) — 17KB
• ea028198201_img2.jpg (GRAPHIC) — 21KB
• ea028198201_img3.jpg (GRAPHIC) — 32KB
• ea028198201_img4.jpg (GRAPHIC) — 30KB
• ea028198201_img5.jpg (GRAPHIC) — 32KB
• ea028198201_img6.jpg (GRAPHIC) — 21KB
• ea028198201_img7.jpg (GRAPHIC) — 18KB
• ea028198201_img8.jpg (GRAPHIC) — 29KB
• ea028198201_img9.jpg (GRAPHIC) — 23KB
• ea028198201_img10.jpg (GRAPHIC) — 26KB
• ea028198201_img11.jpg (GRAPHIC) — 27KB
• ea028198201_img12.jpg (GRAPHIC) — 39KB
• ea028198201_img13.jpg (GRAPHIC) — 32KB
• 0001213900-26-035903.txt ( ) — 8909KB
• uncy-20251231.xsd (EX-101.SCH) — 70KB
• uncy-20251231_cal.xml (EX-101.CAL) — 49KB
• uncy-20251231_def.xml (EX-101.DEF) — 350KB
• uncy-20251231_lab.xml (EX-101.LAB) — 665KB
• uncy-20251231_pre.xml (EX-101.PRE) — 381KB
• ea0281982-10k_unicycive_htm.xml (XML) — 915KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 39 Item 1B. Unresolved Staff Comments 70 Item 1C. Cybersecurity 70 Item 2.

Properties

Properties 71 Item 3.

Legal Proceedings

Legal Proceedings 71 Item 4. Mine Safety Disclosures 71 Part II 72 Item 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 72 Item 6. [Reserved] 72 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 73 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 80 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 81 Item 9A.

Controls and Procedures

Controls and Procedures 81 Item 9B. Other Information 8 1 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 81 Part III 82 Item 10. Directors, Executive Officers and Corporate Governance 82 Item 11.

Executive Compensation

Executive Compensation 82 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 82 Item 13. Certain Relationships and Related Transactions, and Director Independence 82 Item 14. Principal Accountant Fees and Services 82 Part IV 83 Item 15. Exhibit and Financial Statement Schedules 83 Item 16. Form 10-K Summary 84

Signatures

Signatures 85 -i- CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by such forward-looking terminology as "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking the risks and uncertainties inherent in our statements regarding: our projected financial position and estimated cash burn rate; our estimates regarding expenses, future revenues, and capital requirements; our ability to continue as a going concern; our need to raise substantial additional capital to fund our operation; the success, cost, and timing of our clinical trials; our dependence on third parties in the conduct of our clinical trials; our ability to obtain the necessary regulatory approvals to market and commercialize our product candidates; the ultimate impact of the COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; the potentia

BUSINESS

ITEM 1. BUSINESS Overview We are a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable of accelerating the advancement of promising therapies from discovery to commercialization. Currently, our two programs are focused on kidney disease, an area we believe we have the potential to offer medical benefit. Our initial focus is on developing drugs and getting them approved in the U.S., and then to partner with global biopharmaceutical companies in the rest of the world. As we grow the company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our business model is to license technologies and drugs in order to pursue development, regulatory approval, and commercialization of those products in global markets. Many biotechnology companies utilize similar strategies of in-licensing and then developing and commercializing drugs. We believe, however, that our management team's broad network, expertise in the biopharmaceutical industry, and successful track record gives us an advantage in identifying and bringing these assets into our company. Our current development programs are focused on two novel therapies: oxylanthanum carbonate, a next-generation phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate in development for the treatment of acute kidney injury. oxylanthanum carbonate and UNI-494 were initially developed by and licensed to us from Spectrum Pharmaceuticals ("Spectrum") and Sphaera Pharma, respectively. Spectrum conducted a Phase 1 clinical trial with oxylanthanum carbonate in 2012, prior to the grant of our license in 2018. Sphaera conceived and performed i

View Full Filing

View this 10-K filing on SEC EDGAR